Prognostic factors in invasive carcinoma of the breast

Clinical Oncology

Volumn 10, Issue 1, 1998, Pages 14-17

  Elston, C W ^a   Ellis, I O ^a   Pinder, S E ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; INVASIVE CARCINOMA; MAMMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SEGMENTAL MASTECTOMY; SHORT SURVEY;

EID: 0031891374     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80105-2     Document Type: Review

References (60)

1. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991; 15:334-49.
2. Clarke GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994;30:177-226.
3. Blarney RW. Clinical aspects of malignant disease. In: Elston CW, Ellis IO, editors. Systemic pathology, vol. 13: The breast, 3rd ed. London: Churchill Livingstone, 1998;501-14.
4. Elston CW, Ellis IO. Role of pathology in prognosis and management of breast cancer. In: Elston CW, Ellis IO, editors. Systemic pathology, vol. 13: The breast, 3rd ed. London: Churchill Livingstone, 1998;385-434.
5. Barr LC, Baum M. LTime to abandon TNM staging of breast cancer? Lancet 1992;339:915-7.
6. Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992;339:1245-8.
7. O'Dwyer PJ. Axillary dissection in primary breast cancer; the benefits of node clearance warrant reappraisal [editorial]. BMJ 1992;302:360-1.
8. Steele RJG, Forrest APM, Gibson T. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomised trial. Br J Surg 1985;72:368-9.
9. National Co-ordinating Group for Breast Screening Pathology. Pathology reporting in breast cancer screening, 2nd ed. (NHSBSP Publications, no. 3.) Sheffield, 1995.
10. International Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
11. Galea MH, Athanassiou E, Beel J, et al. Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCRC-11. J Pathol 1991;165:221-7.
12. Fisher BR, Sass R, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Project for breast cancer (protocol no. 4). Discrimination for tenth year treatment failure. Cancer 1984;33:712-23.
13. Veronesi U, Galimberti V, Zurrida S, et al. Prognostic significance of number and level of axillary node metastases in breast cancer. Breast 1993;2:224-8.
14. Galea MH, Blamey RW, Elston CW, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:187-91.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I: The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathoiogy 1991;19:403-10.
16. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
17. European Commission, de Wolf CJM, Perry NM, editors. European guidelines for quality assurance in mammography screening, 2nd ed. Luxembourg: Office for Official Publications of the European Communities, 1996.
18. Connolly JL, Fechner RE, Kempson RL, et al. Recommendations for the reporting of breast carcinoma. Hum Pathol 1996;27:220-4.
19. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma: a reproducibility study. Cancer 1994; 73:2765-70.
20. Frierson HF, Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histological grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;105:195-9.
21. Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas. A study of interobserver agreement. Hum Pathol 1995;26:873-9.
22. Ellis IO, Galca M, Broughton N, et al. Pathological prognostic factors in breast cancer. II: Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992;20:479-89.
23. Pereira H, Pinder SH, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 1995;27:219-26.
24. Domagala W, Markiewski M, Kubiak R, et al. Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive. Virchows Arch A Pathol Anat Histopathol 1993;423:497-502.
25. Harris M, Howell A, Chrissohou M, et al. A comparison of the metastatic pattern of infiltrating lobular and infiltrating duct carcinoma of the breast. Br J Cancer 1984;49:325-31.
26. Anderson TJ, Lamb J, Donnan P, et al. Comparative pathology of breast cancer in a randomized trial of screening. Br J Cancer 1991;64:108-13.
27. Ellis IO, Galea MH, Locker A, et al. Early experience in breast cancer screening: emphasis on development of protocols for triple assessment. The Breast 1993;2:148-53.
28. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer. Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
29. Rosen PP, Groshen S, Saigo S, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-51.
30. Yorkshire Breast Cancer Group. Critical assessment of the clinical TNM system in breast cancer. BMJ 1980;281:134-6.
31. Pain JA, Ebbs S, Henn RPA, et al. Assessment of breast cancer size: a comparison of methods. Eur J Surg Oncol 1992;18:44-8.
32. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am 1990;70:937-67.
33. Bettelheim R, Penman HG, Thornton-Jones H, et al. Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 1984;50:771-7.
34. Pinder SE, Ellis IO, O'Rourke S, et al. Pathological prognostic factors in breast cancer. III: Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up. Histopathology 1994;24:41-7.
35. Davis BW, Gelber R, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary node metastases. Hum Pathol 1985;16:1212-18.
36. Roses DF, Bell DA, Fotte TJ, et al. Pathologic predictors of recurrence in stage I (T1N0M0 and T2N0M0) breast cancer. Am J Clin Pathol 1982;78:817-20.
37. Kemperman H, Borger J, Hart A. et al. Prognostic factors for survival after breast conserving therapy for Stage I and II breast cancer: the role of local recurrence. Eur J Cancer 1995;31A:690-8.
38. O'Rourke S, Galea MH, Euhus D, et al. An audit of local recurrence after simple mastectomy. Br J Surg 1994;81:386-9.
39. Walker RA, Camplejohn RS. DNA flow cytometry of human breast carcinomas and its relationship to transform and epidermal growth factor receptors. J Pathol 1986;150:37.
40. Dowle CS, Owainati A, Robins A, et al. The prognostic significance of the DNA content of human breast cancer. Br J Surg 1987;74:133-6.
41. Veronese SM, Gambacorta M, Gottardi O, et al. Proliferation index as a prognostic marker in breast cancer. Cancer 1993;71:3926-31.
42. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-9.
43. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-6.
44. Williams MR, Todd JH, Ellis IO, et al. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987;55:67-73.
45. Poller DN, Hutchings CE, Galea M, et al. p53 protein expression in human breast cancer: relationship to expression of epidermal growth factor, C-erB-2 protein overexpression, and oestrogen receptor. Br J Cancer 1992;66:583-8.
46. Harris AL. What is the biological, prognostic, and therapeutic role of the EGF receptor in human breast cancer? Breast Cancer Res Treat 1994;29:1-2.
47. Lovekin C, Ellis IO, Locker A, et al. C-erB-2 oncoprotein in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
48. Barnes DM. c-erbB-2 amplification in mammary carcinoma. J Cell Biochem Suppl 1993;1:132-8.
49. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. A review of the literature involving over 9000 patients. Appl Immunohistochem 1996;4:106-16.
50. O'Donoghue AE, Poller DN, Bell JA, et al. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat 1995;33:137-45.
51. Joensuu H, Toikkanen S, Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 1995;71:155-9.
52. Weidner N, Carroll RP, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostatic cancer. Am J Pathol 1993;143:401-9.
53. Goulding H, Nik Abdul Rashid NF, Robertson JF. Assessment of angiogenesis in breast cancer. An important factor in prognosis? Hum Pathol 1995;26:1196-200.
54. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997;30:294-301.
55. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
56. Brown JM, Benson EA, Jones M. Confirmation of a long-term prognostic index in breast cancer. Breast 1993;2:144-7.
57. Balslev I, Axelsson CK, Zedelev K, et al. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994;32:281-90.
58. Robertson JFR, Ellis IO, Pearson D, et al. Biological factors of prognostic significance in locally advanced breast cancer. Breast Cancer Res Treat 1994;29:259-64.
59. Goulding H, Pinder S, Cannon P, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 1994;26:291-4.
60. Sibbering DM, Galea MH, Morgan DAL, et al. Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. Eur J Cancer 1995;31:2191-5.